Cargando…

Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer

Several studies have evaluated the association between EGLN2 4-bp insertion/deletion (ins/del) polymorphism (rs10680577) and many cancers. However, up to date, no study has inspected the impact of rs10680577 polymorphism on prostate cancer (PCa) risk. This case-control study was achieved on 170 path...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahimi, Nahid, Azizi, Mahsa, Bahari, Gholamreza, Narouie, Behzad, Hashemi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541883/
https://www.ncbi.nlm.nih.gov/pubmed/32458625
http://dx.doi.org/10.31557/APJCP.2020.21.5.1221
_version_ 1783591443168755712
author Rahimi, Nahid
Azizi, Mahsa
Bahari, Gholamreza
Narouie, Behzad
Hashemi, Mohammad
author_facet Rahimi, Nahid
Azizi, Mahsa
Bahari, Gholamreza
Narouie, Behzad
Hashemi, Mohammad
author_sort Rahimi, Nahid
collection PubMed
description Several studies have evaluated the association between EGLN2 4-bp insertion/deletion (ins/del) polymorphism (rs10680577) and many cancers. However, up to date, no study has inspected the impact of rs10680577 polymorphism on prostate cancer (PCa) risk. This case-control study was achieved on 170 pathologically confirmed PCa patients and 196 cancer free men to inspect whether rs10680577 variant is related to the risk and clinicopathological features of patients with PCa. Genotyping was performed by mismatched polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The findings did not support an association between the variant with the risk and clinicopathological characteristics of PCa patients. When we pooled our results with six preceding studies, the findings suggested that rs10680577 variant significantly augmented the risk of overall cancer in heterozygous (OR=1.38, 95 % CI=1.26-1.52, p<0.00001, ins/del vs ins/ins), homozygous (OR=1.66, 95 % CI=1.05-2.61, p=0.029, del/del vs ins/ins), codominant (OR=1.44, 95%CI=1.32-1.58, p<0.00001, ins/del+del/del vs ins/ins), and allele (OR=1.32, 95%CI=1.18-1.49, p<0.00001, del vs ins) genetic models. Additional well designed studies with larger sample sizes are necessary to confirm our findings.
format Online
Article
Text
id pubmed-7541883
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-75418832020-10-14 Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer Rahimi, Nahid Azizi, Mahsa Bahari, Gholamreza Narouie, Behzad Hashemi, Mohammad Asian Pac J Cancer Prev Research Article Several studies have evaluated the association between EGLN2 4-bp insertion/deletion (ins/del) polymorphism (rs10680577) and many cancers. However, up to date, no study has inspected the impact of rs10680577 polymorphism on prostate cancer (PCa) risk. This case-control study was achieved on 170 pathologically confirmed PCa patients and 196 cancer free men to inspect whether rs10680577 variant is related to the risk and clinicopathological features of patients with PCa. Genotyping was performed by mismatched polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The findings did not support an association between the variant with the risk and clinicopathological characteristics of PCa patients. When we pooled our results with six preceding studies, the findings suggested that rs10680577 variant significantly augmented the risk of overall cancer in heterozygous (OR=1.38, 95 % CI=1.26-1.52, p<0.00001, ins/del vs ins/ins), homozygous (OR=1.66, 95 % CI=1.05-2.61, p=0.029, del/del vs ins/ins), codominant (OR=1.44, 95%CI=1.32-1.58, p<0.00001, ins/del+del/del vs ins/ins), and allele (OR=1.32, 95%CI=1.18-1.49, p<0.00001, del vs ins) genetic models. Additional well designed studies with larger sample sizes are necessary to confirm our findings. West Asia Organization for Cancer Prevention 2020-05 /pmc/articles/PMC7541883/ /pubmed/32458625 http://dx.doi.org/10.31557/APJCP.2020.21.5.1221 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rahimi, Nahid
Azizi, Mahsa
Bahari, Gholamreza
Narouie, Behzad
Hashemi, Mohammad
Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer
title Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer
title_full Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer
title_fullStr Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer
title_full_unstemmed Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer
title_short Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer
title_sort association of egln2 rs10680577 polymorphism with the risk and clinicopathological features of patients with prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541883/
https://www.ncbi.nlm.nih.gov/pubmed/32458625
http://dx.doi.org/10.31557/APJCP.2020.21.5.1221
work_keys_str_mv AT rahiminahid associationofegln2rs10680577polymorphismwiththeriskandclinicopathologicalfeaturesofpatientswithprostatecancer
AT azizimahsa associationofegln2rs10680577polymorphismwiththeriskandclinicopathologicalfeaturesofpatientswithprostatecancer
AT baharigholamreza associationofegln2rs10680577polymorphismwiththeriskandclinicopathologicalfeaturesofpatientswithprostatecancer
AT narouiebehzad associationofegln2rs10680577polymorphismwiththeriskandclinicopathologicalfeaturesofpatientswithprostatecancer
AT hashemimohammad associationofegln2rs10680577polymorphismwiththeriskandclinicopathologicalfeaturesofpatientswithprostatecancer